-+ 0.00%
-+ 0.00%
-+ 0.00%

SAB Bio Q1 FY26 net loss widens to $18.9 million

PUBT·05/12/2026 11:32:07
Listen to the news
SAB Bio Q1 FY26 net loss widens to $18.9 million
  • SAB Biotherapeutics posted a net loss of USD 18.9 million for Q1 2026, widening from USD 5.2 million a year earlier.
  • R&D expense climbed to USD 13.4 million from USD 7.7 million, while G&A expense rose to USD 6.6 million from USD 3.1 million.
  • Other income fell to USD 1.1 million from USD 5.6 million, driven by a change in fair value of warrant liabilities.
  • Cash, cash equivalents and available-for-sale securities totaled USD 217.6 million at March 31, 2026, reflecting USD 95 million in gross proceeds from a public offering and supporting operational runway through 2028.
  • SAFEGUARD Phase 2b enrollment for SAB-142 remains on track to finish by end of 2026 with topline data expected in 2H 2027, while FDA correspondence confirmed C-peptide AUC may serve as a surrogate endpoint for accelerated approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120730PRIMZONEFULLFEED9716786) on May 12, 2026, and is solely responsible for the information contained therein.